- Home
- QRVO vs BPMC Comparison
QRVO vs BPMC Comparison
Compare QRVO & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- BPMC
- Stock Information
- Founded
- QRVO 1957
- BPMC 2008
- Country
- QRVO United States
- BPMC United States
- Employees
- QRVO N/A
- BPMC N/A
- Industry
- QRVO Semiconductors
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- BPMC Health Care
- Exchange
- QRVO Nasdaq
- BPMC Nasdaq
- Market Cap
- QRVO 6.0B
- BPMC 5.8B
- IPO Year
- QRVO 1997
- BPMC 2015
- Fundamental
- Price
- QRVO $73.19
- BPMC $97.17
- Analyst Decision
- QRVO Hold
- BPMC Buy
- Analyst Count
- QRVO 19
- BPMC 21
- Target Price
- QRVO $89.89
- BPMC $124.05
- AVG Volume (30 Days)
- QRVO 2.4M
- BPMC 973.2K
- Earning Date
- QRVO 04-29-2025
- BPMC 05-01-2025
- Dividend Yield
- QRVO N/A
- BPMC N/A
- EPS Growth
- QRVO N/A
- BPMC N/A
- EPS
- QRVO 0.58
- BPMC N/A
- Revenue
- QRVO $3,718,971,000.00
- BPMC $562,121,000.00
- Revenue This Year
- QRVO $0.51
- BPMC $44.85
- Revenue Next Year
- QRVO $5.78
- BPMC $32.06
- P/E Ratio
- QRVO $124.78
- BPMC N/A
- Revenue Growth
- QRVO N/A
- BPMC 99.19
- 52 Week Low
- QRVO $49.46
- BPMC $73.04
- 52 Week High
- QRVO $130.99
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- QRVO 63.04
- BPMC 59.54
- Support Level
- QRVO $69.03
- BPMC $87.03
- Resistance Level
- QRVO $74.21
- BPMC $104.86
- Average True Range (ATR)
- QRVO 2.38
- BPMC 3.86
- MACD
- QRVO 1.45
- BPMC 1.24
- Stochastic Oscillator
- QRVO 93.62
- BPMC 64.38
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.